索拉非尼靶向治疗联合CIK对晚期肝细胞癌患者免疫功能和毒性反应的影响  

Effect of Sorafenib Targeted Therapy Combined with CIK Cells on the Immune Function and Adverse Reaction of Patients with Advanced Hepatocellular Carcinoma

作　　者：韩涛[1] 马东初[2] 丁震宇[1] 郭放[1] 刘兆喆[1] 祁馨卉[1] 韩雅玲[3] 谢晓冬[1] 

机构地区：[1]沈阳军区总医院全军肿瘤诊治中心肿瘤科,沈阳110086 [2]沈阳军区总医院医学实验科,沈阳110086 [3]沈阳军区总医院心血管内科,沈阳110086

出　　处：《解放军医药杂志》2015年第1期41-43,51,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：科技部十二五重大新药创制平台子课题(2012ZX-09303016-002);辽宁省科技攻关计划课题(2012225019)

摘　　要：目的研究索拉非尼靶向治疗联合细胞因子诱导杀伤细胞(CIK)对晚期肝细胞癌患者细胞免疫功能和治疗相关毒性反应的影响。方法收集2011年3月—2013年7月24例确诊为肝细胞癌的患者,索拉非尼联合CIK治疗11例为A组;单用索拉非尼治疗13例为B组,应用统计学软件对相关数据进行比较分析。结果治疗后A组患者血清CD3、CD4、CD4/CD8明显高于B组,CD8明显低于B组(P<0.05),A组疲倦、失眠、腹泻以及食欲下降等毒性反应发生率明显低于B组(P<0.05)。结论接受索拉非尼治疗的肝细胞癌患者联合CIK细胞免疫治疗能很好地改善患者细胞免疫功能,并能降低靶向药物相关毒性反应。Objective To study the effect of Sorafenib targeted therapy combined with CIK（ cytokine-induced killer） cells on the immune function and the toxic reactions of patients with advanced hepatocellular carcinoma. Methods A total of 24 patients confirmed as having hepatocellular carcinoma during March 2011 and July 2013 were divided into group A（ n = 11） and B（ n = 13）. Group A was treated with Sorafenib targeted therapy combined with CIK,while group B received only Sorafenib targeted therapy,and then relevant data was analyzed with statistical software. Results Serum CD3,CD4 and CD4 / CD8 concentrations were significantly higher,while CD8 concentration was significantly lower after the treatment in group A than those in group B（ P〈0. 05）. Incidence rates of adverse reactions such as fatigue,sleeplessness,diarrhea and anepithymia in group A were significantly lower than those in group B（ P〈0. 05）. Conclusion Sorafenib targeted therapy combined with CIK in treatment of patients with hepatocellular carcinoma may significantly improve cellular immune function and reduce the targeting drug-related adverse reactions.

关 键 词：癌 肝细胞 分子靶向治疗 细胞因子诱导杀伤细胞 

分 类 号：R730.261[医药卫生—肿瘤]